Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

ESMO 2024

Lung, Respiratory and Thoracic Cancer

MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC

ELCC 2025

Lung, Respiratory and Thoracic Cancer

LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC

Lung, Respiratory and Thoracic Cancer

Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study

J Thorac Oncol

Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Tejado Gallegos LF, Donner N, Elsayed M, Huggenberger R, Van Tu D

doi: 10.1016/j.jtho.2024.06.008

Multiple Myeloma (MM)

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

Leuk Lymphoma

Knauf W, Uhlig J, von der Heyde E, Losem C, Ammon A, Nusch A, Schlag R, Schulz H, Janssen J, Welslau M, Wilop S, Vannier C, Siebenbach HU, Serrer L, Schuch A, Woerner SM, Engelhardt M, Potthoff K

doi: 10.1080/10428194.2024.2436034

APCCC 2024

Genitourinary Cancer

Patient selection for radioligand therapy

ELCC 2025

Lung, Respiratory and Thoracic Cancer

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

Lung, Respiratory and Thoracic Cancer

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

Eur J Cancer

Liu SY, Erazo T, Jee J, Arfe A, Gupta A, Pike LRG, Santini FC, Daly B, Schoenfeld A, Eichholz J, Johnson K, Martinez A, Sui J, Riaz N, Chang J, Yang SR, Travis W, Arcila ME, Guo J, Gagne E, Garg K, Baehner F, Lee NY, Drilon A, Kris MG, Scher HI, Razavi P, Gomez DR, Jones DR, Rudin CM, Chandarlapaty S, Isbell JM, Li BT

doi: 10.1016/j.ejca.2024.114257

Related content

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC

LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC

Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

Patient selection for radioligand therapy

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Advancing Breast Cancer Treatment with Elacestrant

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer